Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Process design and development of a mammalian cell perfusion culture in shake-tube and benchtop bioreactors.

Wolf MKF, Müller A, Souquet J, Broly H, Morbidelli M.

Biotechnol Bioeng. 2019 Aug;116(8):1973-1985. doi: 10.1002/bit.26999. Epub 2019 May 19.

PMID:
31038199
2.

Continuous and Integrated Expression and Purification of Recombinant Antibodies.

Vogg S, Wolf MKF, Morbidelli M.

Methods Mol Biol. 2018;1850:147-178. doi: 10.1007/978-1-4939-8730-6_11.

PMID:
30242686
3.

Development of a shake tube-based scale-down model for perfusion cultures.

Wolf MKF, Lorenz V, Karst DJ, Souquet J, Broly H, Morbidelli M.

Biotechnol Bioeng. 2018 Nov;115(11):2703-2713. doi: 10.1002/bit.26804. Epub 2018 Sep 10.

PMID:
30039852
4.

Improved Performance in Mammalian Cell Perfusion Cultures by Growth Inhibition.

Wolf MKF, Closet A, Bzowska M, Bielser JM, Souquet J, Broly H, Morbidelli M.

Biotechnol J. 2019 Feb;14(2):e1700722. doi: 10.1002/biot.201700722. Epub 2018 Jun 4.

PMID:
29781256
5.

Preoperative 3D imaging in maxillary sinus: brief review of the literature and case report.

Wolf MK, Rostetter C, Stadlinger B, Locher M, Damerau G.

Quintessence Int. 2015 Jul-Aug;46(7):627-31. doi: 10.3290/j.qi.a33930. Review.

PMID:
25918753
6.

Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.

McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.

Vaccine. 2008 Jun 19;26(26):3291-6. doi: 10.1016/j.vaccine.2008.03.079. Epub 2008 Apr 16.

PMID:
18468742
7.

Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.

Coster TS, Wolf MK, Hall ER, Cassels FJ, Taylor DN, Liu CT, Trespalacios FC, DeLorimier A, Angleberger DR, McQueen CE.

Infect Immun. 2007 Jan;75(1):252-9. Epub 2006 Oct 30.

8.

Bacterial infections of the small intestine and colon.

Wolf MK.

Curr Opin Gastroenterol. 2000 Jan;16(1):4-11.

PMID:
17024009
9.

Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, Cohen D, Wolf MK, Venkatesan MM, Hale TL.

Infect Immun. 2005 Dec;73(12):8027-32.

10.

The nuclear exosome contributes to autogenous control of NAB2 mRNA levels.

Roth KM, Wolf MK, Rossi M, Butler JS.

Mol Cell Biol. 2005 Mar;25(5):1577-85.

11.

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.

Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB.

J Clin Oncol. 2005 May 1;23(13):2946-54. Epub 2005 Feb 7.

PMID:
15699477
12.

National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions.

Koo LC, Clark JA, Quesenberry CP, Higenbottam T, Nyberg F, Wolf MK, Steinberg MH, Forsythe BH.

Pharmacoepidemiol Drug Saf. 2005 Nov;14(11):775-87.

PMID:
15654720
13.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):785-94.

PMID:
14990633
14.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH.

J Clin Oncol. 2004 Mar 1;22(5):777-84.

PMID:
14990632
15.

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL.

Infect Immun. 2004 Feb;72(2):923-30.

16.

Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes.

Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, Garrett-Engele P, Rush CM, Bard M, Schimmack G, Phillips JW, Roberts CJ, Shoemaker DD.

Cell. 2004 Jan 9;116(1):121-37.

17.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC.

JAMA. 2003 Oct 22;290(16):2149-58.

PMID:
14570950
18.

Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.

Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, Newcomer RL, Davachi MA, Taylor DN, McQueen CE.

Vaccine. 2003 Jan 17;21(5-6):341-6.

PMID:
12531630
19.

Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Güereña-Burgueño F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova GV, Alving CR, Glenn GM.

Infect Immun. 2002 Apr;70(4):1874-80.

20.

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH.

J Clin Epidemiol. 2002 Mar;55(3):285-95.

PMID:
11864800
21.

Educating the next generation of physicians about stroke: incorporating stroke prevention into the medical school curriculum.

Billings-Gagliardi S, Fontneau NM, Wolf MK, Barrett SV, Hademenos G, Mazor KM.

Stroke. 2001 Dec 1;32(12):2854-9.

PMID:
11739987
22.

Towards the reconstruction of central nervous system white matter using neural precursor cells.

Mitome M, Low HP, van den Pol A, Nunnari JJ, Wolf MK, Billings-Gagliardi S, Schwartz WJ.

Brain. 2001 Nov;124(Pt 11):2147-61.

PMID:
11673317
23.

Enteropathogenic Escherichia coli strain RDEC-1 produces a novel electrogenic factor active on rabbit ileum in vitro.

Raimondi F, Kaper JB, Boedeker EC, Wolf MK, Guandalini S, Fasano A.

J Pediatr Gastroenterol Nutr. 2001 Feb;32(2):122-6.

PMID:
11321378
24.

Rumpshaker behaves like juvenile-lethal Plp mutations when combined with shiverer in double mutant mice.

Billings-Gagliardi S, Nunnari JJ, Wolf MK.

Dev Neurosci. 2001;23(1):7-16.

PMID:
11173922
25.

Quaking*shiverer double-mutant mice survive for at least 100 days with no CNS myelin.

Wolf MK, Nunnari JN, Billings-Gagliardi S.

Dev Neurosci. 1999;21(6):483-90.

PMID:
10640866
26.

Evidence that CNS hypomyelination does not cause death of jimpy-msd mutant mice.

Billings-Gagliardi S, Nunnari JN, Nadon NL, Wolf MK.

Dev Neurosci. 1999;21(6):473-82.

PMID:
10640865
28.

Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.

Kish JA, Wolf MK, Schellhammer PF, Hussain MH, Einstein AB, Crawford ED.

Am J Clin Oncol. 1997 Aug;20(4):327-30.

PMID:
9256883
29.

Using interdisciplinary educational strategies to improve the teaching of cellular neurodevelopment.

Billings-Gagliardi S, Manfred LM, Wolf MK.

Acad Med. 1997 May;72(5):420-1. No abstract available.

PMID:
10676339
30.

The CS6 colonization factor of human enterotoxigenic Escherichia coli contains two heterologous major subunits.

Wolf MK, de Haan LA, Cassels FJ, Willshaw GA, Warren R, Boedeker EC, Gaastra W.

FEMS Microbiol Lett. 1997 Mar 1;148(1):35-42.

31.

Regulation of cytoskeleton by myelin components: studies on shiverer oligodendrocytes carrying an Mbp transgene.

Dyer CA, Phillbotte T, Wolf MK, Billings-Gagliardi S.

Dev Neurosci. 1997;19(5):395-409.

PMID:
9323460
32.

Jimpy-4J mouse has a missense mutation in exon 2 of the Plp gene.

Pearsall GB, Nadon NL, Wolf MK, Billings-Gagliardi S.

Dev Neurosci. 1997;19(4):337-41.

PMID:
9215879
33.
36.

Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.

Williamson SK, Wolf MK, Eisenberger MA, O'Rourke MA, Brannon W, Crawford ED.

Am J Clin Oncol. 1996 Aug;19(4):368-70.

PMID:
8677906
37.

Linking basic, clinical, and social sciences.

Billings-Gagliardi S, Stone SL, Wolf MK.

Acad Med. 1996 May;71(5):535-6. No abstract available.

PMID:
10676272
38.

Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group Study.

Marshall ME, Wolf MK, Crawford ED, Weiss GR, Ahmann F, Meyers FJ, Blumenstein B, Eisenberger M, Einstein AB.

Am J Clin Oncol. 1995 Oct;18(5):400-2.

PMID:
7572756
39.

Colonization factors of diarrheagenic E. coli and their intestinal receptors.

Cassels FJ, Wolf MK.

J Ind Microbiol. 1995 Sep;15(3):214-26. Review.

PMID:
8519480
40.

A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.

Whitehead RP, Wolf MK, Solanki DL, Hemstreet GP 3rd, Benedetto P, Richman SP, Flanigan RC, Crawford ED.

J Immunother Emphasis Tumor Immunol. 1995 Aug;18(2):104-14.

PMID:
8574465
41.

Jimpy 4J: a new X-linked mouse mutation producing severe CNS hypomyelination.

Billings-Gagliardi S, Kirschner DA, Nadon NL, DiBenedetto LM, Karthigasan J, Lane P, Pearsall GB, Wolf MK.

Dev Neurosci. 1995;17(5-6):300-10.

PMID:
8829919
42.

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.

Williamson SK, Wolf MK, Eisenberger MA, O'Rourke M, Brannon W, Crawford ED.

Invest New Drugs. 1995;13(2):167-70.

PMID:
8617581
43.

Cytoskeleton in myelin-basic-protein-deficient shiverer oligodendrocytes.

Dyer CA, Philibotte TM, Billings-Gagliardi S, Wolf MK.

Dev Neurosci. 1995;17(1):53-62.

PMID:
7542583
44.

Myelin basic protein mediates extracellular signals that regulate microtubule stability in oligodendrocyte membrane sheets.

Dyer CA, Philibotte TM, Wolf MK, Billings-Gagliardi S.

J Neurosci Res. 1994 Sep 1;39(1):97-107.

PMID:
7528819
45.

A case of diarrhea, bacteremia, and fever caused by a novel strain of Escherichia coli.

Bratoeva MP, Wolf MK, Marks JK, Cantey JR.

J Clin Microbiol. 1994 May;32(5):1383-6.

46.

Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group study.

Marshall ME, Wolf MK, Crawford ED, Taylor S, Blumenstein B, Flanigan R, Meyers FJ, Hynes HE, Barlogie B, Eisenberger M.

Invest New Drugs. 1993 May-Aug;11(2-3):207-9.

PMID:
8262733
47.

Characterization of enterotoxigenic Escherichia coli isolated from U.S. troops deployed to the Middle East.

Wolf MK, Taylor DN, Boedeker EC, Hyams KC, Maneval DR, Levine MM, Tamura K, Wilson RA, Echeverria P.

J Clin Microbiol. 1993 Apr;31(4):851-6.

48.

Shiverer jimpy double mutant mice. V. Correlation of genotype and myelin proteins.

Sinclair A, Raz Y, Kirschner DA, Villa-Komaroff L, Wolf MK, Billings-Gagliardi S.

Dev Neurosci. 1991;13(3):138-42.

PMID:
1721567
49.

Quantitative differences between homozygous 'USA' and 'Swiss' mld mutant mice.

Billings-Gagliardi S, Tosic M, Matthieu JM, Kirschner DA, Wolf MK.

Dev Neurosci. 1991;13(2):87-97.

PMID:
1712720

Supplemental Content

Support Center